Search Result

Results for "

c-met

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Met/HGFR (148) Akt (6) AMPK (1) Anaplastic lymphoma kinase (ALK) (9) Angiotensin Receptor (2) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (44) Autophagy (15) Bacterial (2) Bcl-2 Family (1) c-Kit (8) Caspase (1) CDK (1) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) Discoidin Domain Receptor (2) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (9) Endogenous Metabolite (1) ERK (1) Estrogen Receptor/ERR (1) FGFR (1) FLT3 (9) G-quadruplex (1) Glutaminase (3) HDAC (3) HIF/HIF Prolyl-Hydroxylase (2) iGluR (3) Isotope-Labeled Compounds (5) JNK (1) MDM-2/p53 (1) Mitosis (1) MMP (1) mTOR (2) NF-κB (1) P-glycoprotein (1) p38 MAPK (3) PARP (1) PDGFR (4) Phosphatase (1) PI3K (2) Polo-like Kinase (PLK) (1) PROTAC Linkers (1) PROTACs (8) RAD51 (3) Raf (2) Reference Standards (8) RET (4) RIP kinase (1) ROS Kinase (10) Small Interfering RNA (siRNA) (2) Src (1) STAT (3) TAM Receptor (11) Target Protein Ligand-Linker Conjugates (3) Topoisomerase (3) Trk Receptor (2) Tyrosinase (3) VEGFR (24)
By Research Areas:	Cancer (156) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (4) Metabolic Disease (6) Neurological Disease (9)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

170

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: c-Met/HGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15735

c-Met inhibitor 1 1 Publications Verification	c-Met/HGFR	Cancer
c-Met inhibitor 1 is an orally active *c-Met* inhibitor. c-Met inhibitor 1 can inhibit *c-Met* phosphorylation with an IC₅₀ of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma .

HY-175333

c-Met ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates c-Met/HGFR	Cancer
c-Met ligand-Linker Conjugate 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for *c-Met* (HY-W425461) and a PROTAC linker (HY-151862), which recruits E3 ligases. c-Met ligand-Linker Conjugate 1 can be used for synthesis of PROTAC c-Met degrader-5 (HY-175320) .

HY-162679

c-Met degrader-1	c-Met/HGFR Apoptosis	Cancer
c-Met degrader-1 (Compound H11) is an orally active *c-Met* degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .

HY-175337

c-Met ligand-Linker Conjugate 2	Target Protein Ligand-Linker Conjugates c-Met/HGFR	Cancer
c-Met ligand-Linker Conjugate 2 is a synthesized target protein ligand-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC c-Met degrader-6 (HY-175321). PROTAC c-Met degrader-6 is a c-Met PROTAC degrader with anti-tumor activity ^{[1] ^.}

HY-149880

c-Met-IN-18	c-Met/HGFR	Cancer
c-Met-IN-18 is ATP competitive type-III c-MET inhibitor of WT and D1228V mutant c-MET. c-Met-IN-18 has inhibitory for WT/D1228V with an IC₅₀ value of 0.013/0.20 ^e.c-Met-IN-18 can be used for the research of c-MET driven cancers . c-Met-IN-18 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115937

c-Met-IN-9	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC₅₀ of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities .

HY-150582

c-Met-IN-14	c-Met/HGFR c-Kit FLT3 Apoptosis	Cancer
c-Met-IN-14 (compound 26af) is a selective inhibitor of *c-Met* kinase from N-sulfonylamidine-based derivatives, with an IC₅₀ value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner .

HY-157302

c-Met-IN-21	c-Met/HGFR	Cancer
c-Met-IN-21 (compound 54) is a *c-met* inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

HY-147694

c-Met-IN-11	c-Met/HGFR VEGFR	Cancer
c-Met-IN-11 (compound 3) is a potent *c-MET* and VEGFR-2 inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively .

HY-157387

c-Met-IN-22	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-22 (compound 51am) is an orally active inhibitor against *c-Met* with an IC₅₀ value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis .

HY-153831

c-Met-IN-17	c-Met/HGFR	Cancer
c-Met-IN-17 is a potent *c-Met* kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162803

c-Met-IN-24	Apoptosis c-Met/HGFR STAT	Cancer
c-Met-IN-24 (compound 3g) is a dual-target inhibitor of STAT-3 ( =4.7 μM) and *c-MET* ( =12.67 μM) with anticancer activity. c-Met-IN-24 arrests the G2/M cell cycle and induces apoptosis in SNB-75 cells. c-Met-IN-24 can be used in the study of central nervous system cancers .

HY-18711

SCR-1481B1 free base metatinib free base; c-met inhibitor 2 free base	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .

HY-148279

c-Met-IN-15	c-Met/HGFR	Cancer
c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II *c-Met* kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-161353

c-Met-IN-23	P-glycoprotein c-Met/HGFR	Cancer
c-Met-IN-23 (Compound 12g) is a *c-Met* inhibitor (IC₅₀ = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent .

HY-120908

c-Met-IN-16	c-Met/HGFR	Cancer
c-Met-IN-16 is a *c-Met* inhibitor that can be used for cancer research .

HY-101773

c-Met-IN-2	c-Met/HGFR	Cancer
c-Met-IN-2 is a potent, selective and orally available *c-Met* inhibitor, with an IC₅₀ of 0.6 nM, with antitumor activity.

HY-150004

c-Met/HDAC-IN-3	c-Met/HGFR HDAC Apoptosis	Cancer
c-Met/HDAC-IN-3 (Compound 15f) is a dual *c-Met* and HDAC inhibitor with IC₅₀ values of 12.50 nM and 26.97 nM against c-Met and HDAC1, respectively. c-Met/HDAC-IN-3 induces apoptosis and cause cell cycle arrest in G2/M phase .

HY-101031

c-Met-IN-1	c-Met/HGFR	Cancer
c-met-IN-1 (compound 16) is a potent and selective *c-Met* inhibitor, with IC₅₀ of 1.1 nM, with antitumor activity. .

HY-168268

c-Met-IN-26	c-Met/HGFR	Cancer
c-Met-IN-26 (compound 1-170) is a potent inhibitor of *c-Met, with the IC₅₀* of 1.6 nM. c-Met-IN-26 palys an important role in cancer research .

HY-150576

c-Met-IN-13	c-Met/HGFR	Cancer
c-Met-IN-13 is a potent *c-Met* inhibitor with an IC₅₀ value of 2.43 nM. c-Met-IN-13 shows excellent cytotoxicity for cancer cells. c-Met-IN-13 shows antiproliferative activity in a concentration- and time- dependent manner. c-Met-IN-13 has the potential for the research of cancer .

HY-143462

c-Met/HDAC-IN-2	HDAC c-Met/HGFR Apoptosis	Cancer
c-Met/HDAC-IN-2 is a highly potent *c-Met* and HDAC dual inhibitor with IC₅₀s of 18.49 nM and 5.40 nM for HDAC1 and *c-Met, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines. c-Met/HDAC-IN-2 can cause G2/M-phase arrest and induce apoptosis* in HCT-116. c-Met/HDAC-IN-2 can be used for researching anti-cancer resistance .

HY-162868

c-Met/HDAC-IN-4	c-Met/HGFR HDAC Apoptosis	Cancer
c-Met/HDAC-IN-4 is a dual inhibitor of *c-Met/HDAC. The IC₅₀* value of c-Met/HDAC-IN-4 for c-Met is 28.92 nM. c-Met/HDAC-IN-4 can induce G₀/G₁ phase cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells, and it inhibits the proliferation and invasion of breast cancer cell lines .

HY-156098

c-Met-IN-19	c-Met/HGFR	Cancer
c-Met-IN-19 (Compound 21j) is a *c-Met* inhibitor (IC₅₀: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC₅₀s of 0.25, 0.36, 0.98, 0.76 μM .

HY-146274

c-Met-IN-10	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC₅₀ value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC₅₀s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer .

HY-18711A

SCR-1481B1 metatinib anhydrous; c-met inhibitor 2	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 (Metatinib anhydrous) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

HY-170954

C-Met/Axl-IN-1	Apoptosis c-Met/HGFR TAM Receptor	Cancer
C-Met/Axl-IN-1 (Compound 22a) is an orally active and selective type II *c-Met/Axl* inhibitor with IC₅₀ values of 1 nM and 10 nM, respectively. C-Met/Axl-IN-1 can inhibit proliferation, induce cell cycle arrest and apoptosis of tumor cells. C-Met/Axl-IN-1 has strong anti-tumor activity .

HY-145865

c-Met/MEK1/Flt-3-IN-1	Apoptosis	Cancer
Antiproliferative against-3 (comp 33) shows a prominent activity against Hela (IC₅₀ = 0.21 µM), A549 (IC₅₀ = 0.39 µM), and MCF-7 (IC₅₀ = 0.33 µM), respectively. Antiproliferative against-3 (comp 33) also dose dependently induces apoptosis by arresting A549 cells at G1 phase .

HY-175320

*PROTAC c-Met* degrader-5**	PROTACs c-Met/HGFR Apoptosis STAT	Cancer
PROTAC c-Met degrader-5 (Compound D19) is an orally active *c-Met* PROTAC degrader with DC₅₀s of 0.42 and 0.32 nM in EBC-1 and Hs746T cells, respectively. PROTAC c-Met degrader-5 significantly induces cell apoptosis, G1 cell cycle arrest, and inhibits cell migration and invasion. PROTAC c-Met degrader-5 has potent antiproliferative and degradation efficacy against c-Met-addicted cancer cells and Tepotinib (HY-14721)-resistant cancer cells . Pink: c-Met ligand (HY-W425461); Blue: CRBN ligase ligand (HY-14658); Black: linker

HY-168910

*PROTAC c-Met* degrader-3**	PROTACs c-Met/HGFR	Cancer
PROTAC c-Met degrader-3 (Compound 22b) is a *c-Met* PROTAC degrader. PROTAC c-Met degrader-3 promotes ubiquitination and degradation of c-Met (DC₅₀ of 0.59 nM in EBC-1 cells). PROTAC c-Met degrader-3 can be used for the research of lung cancer (Pink: c-Met ligand (HY-14721); Blue: E3 ligase CRBN ligand (HY-W249500); linker + E3 ligase ligand (HY-168911)) .

HY-175321

*PROTAC c-Met* degrader-6**	PROTACs c-Met/HGFR Apoptosis	Cancer
PROTAC c-Met degrader-6 is a potent and orally active c-Met PROTACdegrader. PROTAC c-Met degrader-6 significantly induces the degradation of the c-Met protein with DC₅₀s of 0.52 nM and 0.45 nM in EBC-1 and Hs746T. PROTAC c-Met degrader-6 almost abrogates the migratory and invasion abilities of tumor cells and significantly induces the apoptosis and blocks the cell cycle in the G0/G1 phase. PROTAC c-Met degrader-6 can be used for the study of various cancers such as non-small cell lung cancer and stomach cancer (Pink: c-Met ligand (HY-W425461); Blue: E3 ligand (HY-14658); Black: Linker (HY-20797)) .

HY-168135

*PROTAC c-Met* degrader-1**	PROTACs c-Met/HGFR	Cancer
PROTAC c-Met degrader-1 (Compound Met-DD4) is an orally active PROTAC degrader for *c-Met* with a DC₅₀ of 6.21 nM. PROTAC c-Met degrader-1 inhibits the proliferation of c-Met-addicted cell MKN-45 with an IC₅₀ of 4.37 nM, and arrests the cell cycle at G0/G1 phase. PROTAC c-Met degrader-1 exhibits antitumor efficacy in MKN-45 xenograft mouse models . (Pink: Ligand for target protein (HY-13404); Blue: Ligand for E3 ligase (HY-W087383); Black: Linker (HY-W074901))

HY-170335

*PROTAC c-Met* degrader-2**	PROTACs c-Met/HGFR	Others
PROTAC c-Met degrader-2 (PROTAC2) is a PROTAC-based *c-Met* degrader, with a DC₅₀ of 50 nM (Pink: Foretinib (HY-10338); Black: linker (HY-45124); Blue: CRBN ligand Thalidomide-4-O-C2-NH2 (HY-136162A)) .

HY-163006

*EGFR/c-Met-IN-1*	EGFR c-Met/HGFR	Cancer
EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of *EGFR/c-Met. The IC₅₀ for inhibiting EGFR ^L858R and c-Met* is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo .

HY-161141

*EGFR/c-Met-IN-2*	c-Met/HGFR	Cancer
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of *EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met*-IN-2 has antitumor activity .

HY-178438

*Mer/c-Met-IN-1*	c-Met/HGFR Apoptosis	Cancer
Mer/c-Met-IN-1 is a potent Mer/c-met dual inhibitor with IC₅₀ values of 1 and 19 nM. Mer/c-Met-IN-1 can inhibit cancer cells proliferation, migration and induce apoptosis. Mer/c-Met-IN-1 can be used for the research of cancer, such as colon cancer .

HY-149674

*VEGFR-2/c-Met-IN-1*	VEGFR	Cancer
VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and *c-Met* with *IC₅₀s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity .*

HY-P991177

*Anti-c-Met/HGFR Antibody* RC-108 antibody	c-Met/HGFR	Cancer
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets *c-Met*. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-149675

*VEGFR-2/c-Met-IN-2*	VEGFR c-Met/HGFR	Cancer
VEGFR-2/c-Met-IN-2 (compound 3e) is a *VEGFR-2/c-Met* inhibitor, with IC₅₀ values of 83 and 48 nM, respectively. VEGFR-2/c-Met-IN-2 exhibits cytotoxic activity against HCT-116 cell line (IC₅₀: 3.403 µM) .

HY-164394

EMD 1204831	c-Met/HGFR	Cancer
EMD 1204831 is a potent and highly selective *c-Met* inhibitor which selectively suppresses the c-Met receptor tyrosine kinase activity with an IC₅₀ of 9 nM. EMD 1204831 can be utilized in cancer research .

HY-161372

*PARP1/c-Met-IN-1*	PARP c-Met/HGFR Apoptosis	Cancer
PARP1/c-Met-IN-1 (Compound 16) is a selective dual inhibitor for PARP1 and *c-Met, with IC₅₀s of 3.3 and 32.2 nM, respectively. PARP1/c-Met-IN-1 induces cell apoptosis* and cell cycle arrest in G2/M phase in MDA-MB-231 cells. PARP1/c-Met-IN-1 exhibits antitumor activity in mice .

HY-P991565

CE-355621	c-Met/HGFR	Cancer
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (K_D = 200 pM, IC₅₀ = 466 pM) in A549 cells and cyno c-Met (K_D = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .

HY-50703

MK-2461 1 Publications Verification	c-Met/HGFR	Cancer
MK-2461 is an ATP-competitive, selective and orally active wild-type and mutant *c-Met* inhibitor (IC₅₀s: 0.4-2.5 nM). MK-2461 also inhibits Ron (IC₅₀ of 7 nM) and Flt1 (IC₅₀ of 10 nM), MK-2461 shows selective for c-MET over other kinases (lC₅₀s = 22-7800 nM). MK-2461 can be used for the study of cancer, such as gastric cancer .

HY-50683

JNJ-38877605 5 Publications Verification	c-Met/HGFR	Metabolic Disease Cancer
JNJ-38877605 is an orally active ATP-competitive inhibitor of *c-Met* with an IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .

HY-133083

BAY-474	c-Met/HGFR	Cancer
BAY-474 is a tyrosine-protein kinase *c-Met* inhibitor. BAY-474 acts as an epigenetics probe .

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective *c-Met* kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

HY-123237

KRC-108	c-Met/HGFR FLT3 Trk Receptor Apoptosis Autophagy	Cancer
KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC₅₀s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for *c-Met, c-Met* M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice .

HY-157551

JNK-IN-16	JNK c-Met/HGFR	Cancer
JNK-IN-16 (MA43 or compound 3a) is a potent JNK and *c-Met* inhibitor with IC₅₀s of 72 nM and 120 nM, respectively. JNK-IN-16 can be used for cancer .

HY-116592

SOMCL-863	c-Met/HGFR	Cancer
SOMCL-863 is a selective and orally active *c-Met* inhibitor with antitumor activity in vitro and in vivo. SOMCL-863 can be utilized in cancer research .

Cat. No.	Product Name

HY-L188

Anti-Brain Cancer Compound Library

1,844 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,844 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

HY-L016

Protein Tyrosine Kinase Compound Library

1,420 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,420 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L101

Anti-Liver Cancer Compound Library

2,503 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,503 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P99391

Telisotuzumab ABT-700	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits *c-Met* receptor-mediated cancer cell proliferation, migration, and invasion .

HY-P99455

Bafisontamab EMB-01	EGFR c-Met/HGFR	Cancer
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and *cMET* with antitumor activity .

HY-P991177

*Anti-c-Met/HGFR Antibody* RC-108 antibody	c-Met/HGFR	Cancer
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets *c-Met*. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991565

CE-355621	c-Met/HGFR	Cancer
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (K_D = 200 pM, IC₅₀ = 466 pM) in A549 cells and cyno c-Met (K_D = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .

HY-P990432

*Anti-HGFR/c-Met* Antibody**	Inhibitory Antibodies	Inflammation/Immunology
Anti-HGFR/c-Met Antibody is a humanized antibody expressed in CHO, targeting *HGFR/c-Met. The Anti-HGFR/c-Met* Antibody contains huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFR/c-Met Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P991589

SFN68 NOV-1105	c-Met/HGFR	Cancer
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits *HGF/c-Met* interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, *c-MET, HIF-1α, and VEGF*. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

HY-P990661

SAIT-301	c-Met/HGFR	Inflammation/Immunology
SAIT-301 is a humanized antibody expressed in CHO cells, targeting *HGFR/c-Met*. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6797

Meleagrin	Infection Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Bacterial c-Met/HGFR Antibiotic
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead *c-Met* inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies .

HY-W015309

Decanoic acid 3 Publications Verification	Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Biological Pesticide Research Agricultural Research	iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of *c-Met* and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-W015309R

Decanoic acid (Standard)	Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

Species:	Human (6)
Tag:	His (5) Avi (2) Fc (1)
Source:	HEK293 (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P70714

	HGFR Protein, Human (HEK293, His) Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase met; met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70715

	HGFR Protein, Human (HEK293, Fc) Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase met; met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, Fc) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P78490

	HGFR Protein, Human (HEK293, His-Avi) met; oncogene met; HGF R; HGF/SF receptor; AUTS9; cmet; met (c-met); RCCP2; SF receptor	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, His-Avi) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P701263

	FITC-Labeled HGFR Protein, Human (HEK293, His) met; AUTS9; HGFR; RCCP2; c-met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. FITC-Labeled HGFR Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled HGFR protein, expressed by HEK293 , with His labeled tag.

HY-P72376

	HGFR Protein, Human (Biotinylated, HEK293, His-Avi) Hepatocyte growth factor receptor; Proto-oncogene c-met; SF receptor; Tyrosine-protein kinase met; met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P72624

	HGFR Protein, Human (495a.a, HEK293, His) Hepatocyte growth factor receptor; HGF receptor; SF receptor; met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (495a.a, HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-W266188

Decanoic acid-13C

Decanoic acid- ¹³C is the ¹³C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-50878S2

Crizotinib-d9

Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878S1

Crizotinib-d8

Crizotinib-d₈ (PF-02341066-d₈) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P84014

	*Met（c-Met） Antibody (YA3711)* HGFR; AUTS9; RCCP2; c-met; DFNB97	WB, IHC-P, ICC/IF, FC, ELISA	Human, Monkey
	Met（c-Met） Antibody (YA3711) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Met（c-Met）.

HY-P86238

	*Met (C-Met) Antibody (YA5930)* met; Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase met	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Met (C-Met) Antibody (YA5930) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Met (C-Met).

HY-P80219

	*Met (C-Met) Antibody (YA298)*	WB, ICC/IF, IHC-P, FC	Human
	Met (C-Met) Antibody (YA298) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Met (C-Met).

HY-P80803

	*Phospho-Met（c-Met） (Tyr1349) Antibody (YA213)* met; Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase met	WB, IP	Human
	Phospho-Met（c-Met） (Tyr1349) Antibody (YA213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Met（c-Met） (Tyr1349).

HY-P80512

	*Phospho-Met（c-Met） Antibody (YA175)*	WB, IHC-P	Human
	Phospho-Met（c-Met） Antibody (YA175) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Met（c-Met）.

HY-P85883

	*Met（c-Met） Antibody (YA5575)* met; Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase met	WB, ICC/IF, ELISA	Human, Mouse, Rat, Monkey
	Met（c-Met） Antibody (YA5575) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Met（c-Met）.

HY-P86152

	*Phospho-c-Met* (Tyr1234/1235) Antibody (YA5844)** Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase met;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-c-Met (Tyr1234/1235) Antibody (YA5844) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-c-Met (Tyr1234/1235).